FAQ/Help |
Calendar |
Search |
Today's Posts |
04-02-2017, 03:20 PM | #1 | ||
|
|||
News Gatherer
Community Support Team
|
Endpoints News Roche, Prothena hustle to PhII with their disease-modifying Parkinson's drug targeting alpha-synuclein Endpoints News Prothena turned up at the big Alzheimer's/Parkinson's conference in Vienna over the weekend to detail early-stage data showing how its Roche-partnered drug PRX002/RG7935 can flush out toxic clusters of alpha-synuclein in Parkinson's patients. And they ... Clinical Results Presented from Prothena's Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS ...Yahoo Finance all 2 news articles » More... |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||